Market closed
Aurinia Pharmaceuticals/$AUPH
14:30
15:25
16:15
17:10
18:00
1D1W1MYTD1Y5YMAX
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.
Ticker
$AUPH
Sector
Trading on
Industry
Biotechnology
Headquarters
Edmonton, Canada
Employees
300
Website
AUPH Metrics
BasicAdvanced
$1.3B
Market cap
-
P/E ratio
-$0.16
EPS
1.46
Beta
-
Dividend rate
Price and volume
Market cap
$1.3B
Beta
1.46
52-week high
$9.98
52-week low
$4.71
Average daily volume
1.5M
Financial strength
Current ratio
5.603
Quick ratio
4.901
Long term debt to equity
18.532
Total debt to equity
22.642
Interest coverage (TTM)
-3.81%
Management effectiveness
Return on assets (TTM)
-2.15%
Return on equity (TTM)
-5.78%
Valuation
Price to revenue (TTM)
5.845
Price to book
3.31
Price to tangible book (TTM)
3.35
Price to free cash flow (TTM)
45.511
Growth
Revenue change (TTM)
38.72%
Earnings per share change (TTM)
-70.99%
3-year revenue growth (CAGR)
45.03%
3-year earnings per share growth (CAGR)
-49.48%
What the Analysts think about AUPH
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Aurinia Pharmaceuticals stock.
AUPH Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
AUPH Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
AUPH News
AllArticlesVideos
Insiders Are Loving These 6 Stocks Right Now
24/7 Wall Street·2 weeks ago
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
Business Wire·1 month ago
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Aurinia Pharmaceuticals stock?
Aurinia Pharmaceuticals (AUPH) has a market cap of $1.3B as of December 26, 2024.
What is the P/E ratio for Aurinia Pharmaceuticals stock?
The price to earnings (P/E) ratio for Aurinia Pharmaceuticals (AUPH) stock is 0 as of December 26, 2024.
Does Aurinia Pharmaceuticals stock pay dividends?
No, Aurinia Pharmaceuticals (AUPH) stock does not pay dividends to its shareholders as of December 26, 2024.
When is the next Aurinia Pharmaceuticals dividend payment date?
Aurinia Pharmaceuticals (AUPH) stock does not pay dividends to its shareholders.
What is the beta indicator for Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals (AUPH) has a beta rating of 1.46. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.